Small cell lung cancer (SCLC) remains a challenge prognostically. A clinically silent early stage and predilection for early metastasis leads to over half of patients presenting with metastatic disease at the time of diagnosis. Akin to many other cancers, once SCLC metastasizes, current therapies begin to lose their effectiveness. The future of SCLC rests in innovative treatments aimed at improving patient outcomes. Chemotherapy and radiation remain the backbone treatment for SCLC. Most patients diagnosed with SCLC begin treatment with combination chemotherapy consisting of a platinum analog and topoisomerase inhibitor with or without concurrent radiation. Disease progression or recurrence warrants new treatment approaches. New chemotherapy combinations and advances in radiation precision offer patients novel approaches using the same backbone of treatment used in many other cancers. The introduction of newer therapeutic approaches, such as immune checkpoint inhibitors, small molecule targeted therapies, bispecific antibodies, and antibody–drug conjugates offer a bright future for patients with SCLC who fail first-line therapy. This review will focus on advancing treatment paradigms for SCLC in the era of precision medicine. Such a study might be helpful for pulmonologists and oncologists to manage precisely patients with SCLC.
小细胞肺癌（SCLC）的预后仍具挑战性。其早期阶段临床症状隐匿且易发生早期转移，导致超过半数患者在确诊时已出现转移性疾病。与许多其他癌症类似，一旦SCLC发生转移，现有疗法的有效性便开始下降。SCLC的未来在于通过创新治疗改善患者预后。化疗和放疗仍是SCLC的核心治疗手段。多数确诊患者首选含铂类药物联合拓扑异构酶抑制剂的化疗方案，并视情况联合放疗。疾病进展或复发需要新的治疗策略。新型化疗组合与精准放疗技术的进步，为患者提供了基于传统治疗框架的创新方案。免疫检查点抑制剂、小分子靶向治疗、双特异性抗体及抗体偶联药物等新型治疗方法的引入，为一线治疗失败的SCLC患者带来了希望。本综述将聚焦精准医学时代下SCLC治疗模式的进展，旨在为呼吸科与肿瘤科医师提供精准管理SCLC患者的参考依据。
The Era of Precision Medicine: Advancing Treatment Paradigms for Small Cell Lung Cancer
肿瘤(癌症)患者之家